News
NERV
2.360
-2.08%
-0.050
*Minerva Neurosciences in Discussions With FDA Over Issues, Clinical Deficiencies Related to Roluperidone >NERV
Dow Jones · 37m ago
BRIEF-Minerva Neurosciences Q1 Net Income USD -8.569 Million
Reuters · 38m ago
MINERVA NEUROSCIENCES INC - QTRLY NET LOSS PER SHARE OF $1.13 BASIC AND DILUTED
Reuters · 39m ago
Press Release: Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. Reports first quarter 2024 financial results and business updates. The Company is a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders. On February 27, 2024, the FDA issued a response to the Company's NDA for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
Dow Jones · 39m ago
Weekly Report: what happened at NERV last week (0422-0426)?
Weekly Report · 1d ago
Weekly Report: what happened at NERV last week (0415-0419)?
Weekly Report · 04/22 11:58
Weekly Report: what happened at NERV last week (0408-0412)?
Weekly Report · 04/15 11:48
MINERVA NEUROSCIENCES INC - ON APRIL 10, GOT NOTICE FROM NASDAQ THAT COMPANY WAS NOT IN COMPLIANCE WITH NASDAQ’S LISTING RULE
Reuters · 04/12 20:08
Weekly Report: what happened at NERV last week (0401-0405)?
Weekly Report · 04/08 11:54
Weekly Report: what happened at NERV last week (0325-0329)?
Weekly Report · 04/01 11:51
Weekly Report: what happened at NERV last week (0318-0322)?
Weekly Report · 03/25 11:54
Weekly Report: what happened at NERV last week (0311-0315)?
Weekly Report · 03/18 11:52
Weekly Report: what happened at NERV last week (0304-0308)?
Weekly Report · 03/11 11:48
Weekly Report: what happened at NERV last week (0226-0301)?
Weekly Report · 03/04 11:51
Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings
The Dow Jones index fell more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28%. J.M. Smucker Company posted better-than-expected earnings for its fourth quarter. Utilities shares rose by 1.2% on Tuesday as energy shares fell by 0.4%. Asian markets closed higher on Tuesday while European shares closed mixed.
Benzinga · 02/27 19:32
BUZZ-U.S. STOCKS ON THE MOVE-Cava, Bank of America, Fractyl Health
Wall Street's main indexes were mixed on Tuesday. The Dow Jones Industrial Average was down 0.41% at 38,910.21. Norwegian Cruise Line Holdings was one of the top percentage gainers on the S&P 500. Investors are awaiting a crucial inflation report and other economic data.
Reuters · 02/27 19:24
Health Care Sector Update for 02/27/2024: VKTX, CAPR, NERV
NASDAQ · 02/27 18:51
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Helix Energy Solutions Group, Inc. Shares dipped 11% to $9.13 on Tuesday. The company posted weak earnings of 6 cents per share. Janux Therapeutics shares jumped 145% after the company announced updated clinical data for both of its clinical programs. Other stocks moving in Tuesday's mid-day session included Viking Therapeutic and Presto Automation.
Benzinga · 02/27 18:18
Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data
FDA issued a Complete Response Letter to Minerva Neurosciences Inc's marketing application for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company's shares are trading lower after the FDA issued the CRL. The FDA cited the company's application lacks clinical deficiencies.
Benzinga · 02/27 17:53
BBAI, CTMX and STRC among mid-day movers
On the Move BBAI, CTMX and STRC among mid-day movers. Janux Therapeutics and BigBear.ai Holdings were among the biggest gainers. Minerva Neurosciences was among the companies that lost ground in the biotech sector.
Seeking Alpha · 02/27 17:52
More
Webull provides a variety of real-time NERV stock news. You can receive the latest news about Minerva Neurosci through multiple platforms. This information may help you make smarter investment decisions.
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.